Hologic

HOLX

Market cap $16.8B

GE HealthCare is gaining ground with strong backlog, AI-driven imaging advances and rising service capture, while Hologic's buyout caps near-term upside.

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

HOLX's $18.3B Blackstone-TPG buyout nears close after Q1 miss. With shares near a $76 cash offer, the upside for HOLX investors looks dim.

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #FDA--Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio.

Review Hologic's (HOLX) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

Hologic slips after a Q1 EPS and revenue miss, as gross margin fell 150 bps with Diagnostics weakness offset by strong GYN Surgical growth.

The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Hologic (HOLX) came out with quarterly earnings of $1.04 per share, missing the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.03 per share a year ago.